GPC
NVCR icon

Garrison Point Capital’s NovoCure NVCR Stock Holding History

Garrison Point Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$232K – 20
2021
Q3 		$232K Hold
2,000
– – 0.07% 19
2021
Q2 		$444K Hold
2,000
– – 0.15% 16
2021
Q1 		$264K Hold
2,000
– – 0.11% 18
2020
Q4 		$346K Hold
2,000
– – 0.17% 16
2020
Q3 		$223K Buy
+2,000
New +$160K 0.12% 20

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Garrison Point Capital's NVCR Position: Q4 2021 in Review

Garrison Point Capital sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 2,000 shares — an estimated $232K sold.

Garrison Point Capital first reported a position in NVCR in Q3 2020 and held it in 5 quarters. The position peaked at $444K in Q2 2021. 312 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Garrison Point Capital reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Garrison Point Capital sold 2,000 NovoCure shares in Q4 2021, an estimated $232K.
  • Garrison Point Capital first reported a position in NovoCure in Q3 2020 and held it in 5 quarters.
  • Garrison Point Capital's NovoCure position peaked at $444K in Q2 2021.
  • 312 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Garrison Point Capital's 13F filing for Q4 2021, filed 10 Feb 2022.